UTHR UNITED THERAPEUTICS Corp
Price Chart
Executive Summary
Four UTHR insiders (CEO, CFO, EVP, Director) sold a total of ~$1.04M in open-market sales over a 7-day window following the Q1 2026 earnings release. The sales are small relative to the $24.4B market cap (~0.004%), and the CEO's and CFO's sales coincide with option exercises and tax-withholding transactions, suggesting routine portfolio management rather than a bearish signal. The cluster is not amplified by the earnings context because the sales are immaterial in size.
Key Financial Metrics
Actionable Insight
This insider cluster is routine and non-informative. The CEO and CFO are exercising options and selling a small fraction of the resulting shares, likely for tax or liquidity purposes. No bearish signal. Monitor the next 10-Q for any guidance revision or pipeline setback, but this filing alone does not warrant action.
Key Facts
- Total open-market sales of ~$1.04M represent ~0.004% of UTHR's $24.4B market cap — well below the 0.1% materiality threshold.
- CEO Rothblatt sold 1,378 shares ($793K) on May 13, but concurrently exercised 9,500 options at $146.03/share ($1.39M), indicating a net cash-neutral position adjustment.
- CFO Edgemond sold 80 shares ($45K) on May 14 after exercising 10,000 options at $135.42/share ($1.35M) on May 11 and 14 — the sales are trivial relative to the option exercises.
- Director Mesa sold 258 shares ($150K) — a routine diversification trade.
- EVP Mahon sold 80 shares ($47K) — de minimis.
- The cluster follows Q1 2026 earnings (May 6) showing a 2% YoY revenue decline to $781.5M and a 15% net income decline to $274.9M — the insider sales are not reacting to new material information.
- All sales are open-market (code S) and occur after option exercises (code M) — consistent with tax-covering or cash-out patterns, not informed selling.
Financial Impact
Total insider sales of ~$1.04M are immaterial relative to $24.4B market cap — no financial impact.
Risk Factors
- Q1 2026 revenue declined 2% YoY and net income fell 15% — the underlying business fundamentals are softening, but this insider cluster does not add incremental negative signal.
- Tyvaso DPI growth (+9% YoY) is offset by Nebulized Tyvaso decline (-22%) and Remodulin decline (-8%), creating competitive uncertainty.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1778879076624 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
Insider Cluster
| $553.04 awaiting T+1 | awaiting T+1 | — | $544.69 (−1.51%) |
|
Jun 5, 2026
4d ago
|
Insider Cluster
| $547.10 awaiting T+1 | awaiting T+1 | — | $544.69 (−0.44%) |
|
Jun 4, 2026
5d ago
|
Insider Cluster
| $547.10 awaiting T+1 | awaiting T+1 | — | $544.69 (−0.44%) |
|
Jun 4, 2026
5d ago
|
Insider Cluster
| $547.10 awaiting T+1 | awaiting T+1 | — | $544.69 (−0.44%) |
|
Jun 3, 2026
6d ago
|
Insider Cluster
| $547.22 $546.37 | ▼ −0.16% | ▲ +2.44% | $544.69 (−0.46%) |
|
May 29, 2026
11d ago
|
Insider Cluster
| $544.45 $539.91 | ▼ −0.83% | ▼ −0.98% | $544.69 (+0.04%) |
|
May 28, 2026
12d ago
|
Insider Cluster
| $553.34 $544.45 | ▼ −1.61% | ▼ −1.86% | $544.69 (−1.56%) |
|
May 27, 2026
13d ago
|
Insider Cluster
| $561.70 $553.34 | ▼ −1.49% | ▼ −1.73% | $544.69 (−3.03%) |
|
May 26, 2026
14d ago
|
Insider Cluster
| $567.74 $561.70 | ▼ −1.06% | ▼ −1.62% | $544.69 (−4.06%) |
|
May 26, 2026
14d ago
|
Insider Cluster
| $567.74 $561.70 | ▼ −1.06% | ▼ −1.62% | $544.69 (−4.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access